Ductal adenocarcinoma (DCP) a variant of acinar adecocarcinoma (ACP), mainly occurs in patients aged 60-70 years. It is a very rare disease accounting for approximately 0.1 to 1% of all prostate cancers. [1] [2] [3] Although its progress is more aggressive than the acinar type, guidelines for its treatment and follow-up have not been confirmed yet. According to Meekset al., the prevalence of ductal typeprostatic cancer has continuously increased in the last few decades and many studies will be needed in the future. 1 DCP usually starts growing like a papillary tumor in the prostatic urethra resulting in symptoms of hematuria and dysuria. 4 This tumor is known to be primarily transferred to the testis, penis, bone and lung as papillary and/or cribriform growths. 4 
CASE
A 54-year-old male patient presented with gross hematuria at our hospital 6 years ago. A prostatic urethra papillary mass was detected on cystoscopy, and the PSA level was 2.16 ng/ml. The patients received a transurethral resection of the prostatic urethra, and pathologic finding was a DCP of mixed cribriform and papillary pattern.
There was no evidence of metastasis in computerized tomography (CT) and bone scan; therefore, we performed a RP, and made a final diagnosis of DCP invading both lobes of the prostate (Fig.   1 ). The seminal vesicle and lymph node was not involved. The surgical resection margin was negative for malignancy. PSA was 0.03 ng/ml at the third month postoperatively. Subsequently, the patient was lost to follow-up. Five years after radical prostatectomy, the patient returned to our hospital with gross hematuria. Cystourethroscopy revealed a papillary mass on the anterior urethra ( Fig. 2A) . PET-CT showed normal findings. PSA level was elevated to 0.653 ng/ml. The patient received a transurethral resection of the urethral mass (Fig. 2B) . PSA decreased to 0.050 ng/ml postoperatively. DCP was confirmed histopathologically (Fig. 3) . Immunostaining findings from the existing prostate cancer showed positive for PSA and negative for high molecular weight cytokeratin, p63 and cytokeratin 20. There was no recurrence until the one year postoperatively. mended that the disease progress should be monitored by transurethral resection of prostate(TURP) and transrectal ultrasonography-guided prostate biopsy before radical surgery. 3 The method of treatment usually depends on the physician's preference and the patient. However, RP is considered necessary in localized cancer. 8 In the Furthermore, there have been no studies on metastasis or recurrence. 9 We removed the recurrent mass from the anterior urethra; there after the elevation levels of PSA declined. Currently, DCP has reported high recurrence rate and malignant prognosis, and continuous close patient observation is necessary.
